tbuckley/cabot-search huggingface dataset:
Aspirin and plasma interleukin-6 in acute coronary syndromes
Authors: N Jenkins
Journal: Cardiovascular Research (1999)

The recent study by Manten et al. [1] demonstrates controlling for aspirin intake, the diagnostic value of elevated plasma interleukin (IL)-6 concentrations in pa-plasma IL-6 in patients presenting with acute coronary tients with acute coronary syndromes, and the calculated syndromes may have been overstated.receiver-operator characteristic curve suggests that this may be diagnostically useful.Whilst these findings appear to confirm those of an earlier study by Biassuci,[2] major References differences between patient subgroups suggest the possibility of confounding from other variables.Of note, 72%
Expression of rheumatoid arthritis in two ethnic Jewish Israeli groups.
Authors: M Amit, D Guedj, A J Wysenbeek
Journal: Annals of the Rheumatic Diseases (1996)

To investigate the expression of rheumatoid arthritis (RA) in Jewish Israeli patients according to ethnic origin.RA patients who were seen in a primary public rheumatology clinic were divided into two groups according to ethnic origin (Sepharadic or Askenazi) and subjected to a cross sectional study. The two groups were compared for history, physical status, and radiographic and laboratory variables. The entire study population was again divided into two groups according to formal educational level, and these were also compared for the same variables as above.The patients of Sepharadic origin had significantly more pathological recordings of pain and fatigue, and greater Ritchie scores than those of Askenazi origin. The Sepharadic group patients were younger, had a lower educational level, and were predominantly female. The more educated group recorded significantly less pathological pain and fatigue, and had smaller Ritchie scores. Functional capacity and global disease severity, assessed by physician and patient, were also reduced in the more educated group. On multiple regression analysis, ethnic origin was found to be independently related to functional class. Education was found to be independently related to the Ritchie score.Disease manifestations in Jewish RA patients of Sepharadic origin are more serious compared with those in patients of Askenazi origin. In addition, low educational level is related to more severe disease manifestations in Israeli RA patients.
Comparative genomic and phylogeographic analysis of Mycobacterium leprae
Authors: Marc Monot, Nadine Honoré, Thierry Garnier, Nora Zidane, Diana Sherafi, Alberto Paniz-Mondolfi, Masanori Matsuoka, G Michael Taylor, Helen D Donoghue, Abi Bouwman, Simon Mays, Claire Watson, Diana Lockwood, Ali Khamesipour, Yahya Dowlati, Shen Jianping, Thomas H Rea, Lucio Vera-Cabrera, Mariane M Stefani, Sayera Banu, Murdo Macdonald, Bishwa Raj Sapkota, John S Spencer, Jérôme Thomas, Keith Harshman, Pushpendra Singh, Philippe Busso, Alexandre Gattiker, Jacques Rougemont, Patrick J Brennan, Stewart T Cole
Journal: Nature Genetics (2009)
Statistical Model to Determine the Relationship of Response and Survival in Patients With Advanced Ovarian Cancer Treated With Chemotherapy
Authors: Valter Torri, Richard Simon, Estelle Russek-Cohen, Douglas Midthune, Michael Friedman
Journal: JNCI Journal of the National Cancer Institute (1992)

A statistically appropriate analysis of the association between survival and response measures in patients with ovarian cancer could help to define the role of response rate in planning, monitoring, and interpreting the results of clinical trials. This study was designed to investigate the relationship between antitumor response determined by clinical or pathological means and survival in patients with advanced ovarian cancer with no previous treatment. We focused on avoiding the limitations of the usual approach of comparing durations of survival for patients responding to therapy with those for nonresponders. A new meta-analytic statistical model we developed was used to analyze data from 26 randomized clinical trials published between 1975 and 1989. Our model incorporates intra-study and inter-study sources of variability in the estimates of response and survival. The study also addresses the methodological problems of evaluating response as a surrogate end point and the relevance of this association to clinical decision making and the design of clinical trials. For 13 studies in which response was pathologically assessed, an improvement in surgically documented complete response rate was associated with an increase in median survival. A similar but apparently smaller effect was found for the association between objective clinical response and median survival in the 25 studies reporting these data. These results suggest that therapeutic measures must produce large improvements in clinical response rates to achieve meaningful effects on complete response rate appears to be more strongly associated with increased median survival and, hence, might be used for interim monitoring in clinical trials, but the role of second-look procedures in clinical management is controversial.[J Natl Cancer Inst 84:407–114,1992]
Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept
Authors: C.E.M. Griffiths, W. Sterry, F. Brock, M. Dilleen, D. Stefanidis, J.M. Germain, L. Mallbris
Journal: British Journal of Dermatology (2014)

Background Etanercept (ETN) 50 mg once weekly (QW) or 50 mg twice weekly (BIW) for 12 weeks, followed by 50 mg QW in all subjects to Week 24 improved psoriasis in patients with concomitant psoriatic arthritis in the PRESTA trial. Objectives To use data from PRESTA to evaluate the effect of ETN in the treatment of psoriasis by Psoriasis Area Severity Index (PASI) body-region and component, and determine if PASI responses correlate with the Dermatology Life Quality Index (DLQI). Methods Median time to 75% improvement in PASI (PASI75), body- and component-specific subscales over 24 weeks were estimated. Pearson correlation coefficients determined the association between DLQI score and PASI total score, body- and component-specific subscales with ETN treatment at baseline and up to Week 24. Results In total, 748 patients from PRESTA were included (ETN 50 mg QW/QW, n = 371; BIW/QW, n = 377). Patients achieved PASI75 total score and 75% improvements in all body regions and components faster on ETN 50 mg BIW/QW than QW/QW (all P < 0·05). Median time to 75% improvement was faster for the head and trunk followed by upper and lower extremities, and for induration and desquamation followed by erythema and total area. Weak to moderately positive correlations between improvements in DLQI and PASI total score (r = 0·223–0·463), all PASI body-specific (r = 0·114–0·432) and component-specific (r = 0·178–0·478) subscales were observed over 24 weeks. Conclusions Etanercept treatment-response appears to occur in a body- and component-specific manner. Changes in quality of life are not captured by PASI or its subscales.
Ethylene Oxide: Allergic Response
Authors: B. H. AVASHIA
Journal: Annals of Internal Medicine (1975)

Comments and Correction1 May 1975Ethylene Oxide: Allergic ResponseB. H. AVASHIA, M.D.B. H. AVASHIA, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-82-5-724_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: In their paper on anaphylaxis from a product or products of ethylene oxide in January issue (Ann Intern Med 82:58-60, 1975), Dr. Poothullil and associates have observed that "previously documented complications of ethylene oxide have not generally been attributed to allergy."I draw attention to a paper by Drs. Sexton and Henson (1). During this experiment three of the subjects became sensitized and developed itching and urticaria after exposure to ethylene oxide. The authors pointed out the ability of ethylene oxide to act as antigen by combining with body protein and elicit an allergic skin reaction....Reference1. SEXTONHENSON RE: Experimental ethylene oxide human skin injuries. Arch Ind Hyg Occup Med 2:549-564, 1950 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Union Carbide Corporation Charleston, West Virginia 25330 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByEthylene Oxide (ETO) as a Major Cause of Anaphylactoid Reactions in Dialysis (A review) 1 May 1975Volume 82, Issue 5Page: 724-724KeywordsAllergy and immunologyAnaphylaxisAntigensEthyleneProteinsPruritusSkin reactionUrticaria Issue Published: 1 May 1975 PDF DownloadLoading ...
Comparison of Symptoms after Vagotomy with Gastrojejunostomy and Partial Gastrectomy
Authors: A. G. Cox
Journal: BMJ (1968)

One mild hypersensitivity reaction was observed in this series of 10 patients, in contrast to a 41% incidence of reactions in cystinurics treated with D-penicillanmine in four other reported series.None of the other side-effects reported elsewhere for D-penicillamine was observed in this study.
T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Authors: Filipe Pinto, Nelma Pértega-Gomes, Márcia S. Pereira, José R. Vizcaíno, Pedro Monteiro, Rui M. Henrique, Fátima Baltazar, Raquel P. Andrade, Rui M. Reis
Journal: Clinical Cancer Research (2014)

Abstract Purpose: Successful therapy of patients with prostate cancer is highly dependent on reliable diagnostic and prognostic biomarkers. Brachyury is considered a negative prognostic factor in colon and lung cancer; however, there are no reports on Brachyury's expression in prostate cancer. Experimental Design: In this study, we aimed to assess the impact of Brachyury expression in prostate tumorigenesis using a large series of human prostate samples comprising benign tissue, prostate intraepithelial neoplasia (PIN) lesions, localized tumor, and metastatic tissues. The results obtained were compared with what can be inferred from the Oncomine database. In addition, multiple in vitro models of prostate cancer were used to dissect the biologic role of Brachyury in prostate cancer progression. Results: We found that Brachyury is significantly overexpressed in prostate cancer and metastatic tumors when compared with normal tissues, both at protein and at mRNA levels. Brachyury expression in the cytoplasm correlates with highly aggressive tumors, whereas the presence of Brachyury in the nucleus is correlated with tumor invasion. We found that Brachyury-positive cells present higher viability, proliferation, migration, and invasion rates than Brachyury-negative cells. Microarray analysis further showed that genes co-expressed with Brachyury are clustered in oncogenic-related pathways, namely cell motility, cell-cycle regulation, and cell metabolism. Conclusions: Collectively, the present study suggests that Brachyury plays an important role in prostate cancer aggressiveness and points, for the first time, to Brachyury as a significant predictor of poor prostate cancer prognosis. Our work paves the way for future studies assessing Brachyury as a possible prostate cancer therapeutic target. Clin Cancer Res; 20(18); 4949–61. ©2014 AACR.
Eculizumab in Severe Shiga-Toxin–Associated HUS
Authors: Anne-Laure Lapeyraque, Michal Malina, Véronique Fremeaux-Bacchi, Tobias Boppel, Michael Kirschfink, Mehdi Oualha, François Proulx, Marie-José Clermont, Françoise Le Deist, Patrick Niaudet, Franz Schaefer
Journal: New England Journal of Medicine (2011)

This letter reports treatment of three children with severe, dialysis-requiring Shiga-toxin–induced hemolytic–uremic syndrome (HUS) with eculizumab, a monoclonal anti-C5 antibody. The condition of all three children improved rapidly.
Computational Genomics: The Medicine of the Future?
Authors: Gail Dutton
Journal: Annals of Internal Medicine (1999)

Currents16 November 1999Computational Genomics: The Medicine of the Future?Gail DuttonGail DuttonAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-10-199911160-00101 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Only a few years ago, computational genomics referred to bioinformatics—the process of using computer algorithms to manage and analyze genomic data. Today, the meaning of the term has broadened along with genomic knowledge. At its most inclusive, it encompasses the development of genomic-based diagnostic and therapeutic tools that eventually will be useful in clinical practice.The Human Genome Project—the heart of the discipline—will probably complete its sequencing efforts within the next 12 to 18 months. The next step will be to identify each gene, ascertain each gene's function within the genome, and determine the proteins that each gene encodes. Both ... Author, Article, and Disclosure InformationAuthors: Gail DuttonAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byReport from the 2nd Summer School in Computational Biology organized by the Queen's University of BelfastSynergy between medical informatics and bioinformatics: facilitating genomic medicine for future health careHigh-throughput epidemiologic typing in clinical microbiologyAntihypertensive pharmacogenetics: getting the right drug into the right patientGenetics of Hypertension, Target-Organ Complications, and Response to Therapy 16 November 1999Volume 131, Issue 10Page: 801-804KeywordsChromosomesComputersDNADatabasesDrugsGenetic testingGeneticsGenomicsResearch laboratoriesSingle nucleotide polymorphism ePublished: 15 August 2000 Issue Published: 16 November 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.Loading ...
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An international oncology study group (IOSG) phase II protocol
Authors: Francis J. Giles, Nicholas R. Wickham, Bernardo L. Rapoport, George Somlo, Stephen W. Lim, Jianqin Shan, Anne M. Lynott
Journal: American Journal of Hematology (2000)

A 4- day continuous intravenous (CIV) infusion of vincristine and doxorubicin with high-dose dexamethasone (VAD) regimen is a standard refractory multiple myeloma (MM) regimen. A Phase II study of a CEVAD regimen, i.e., VAD plus etoposide administered as a 96-hr continuous infusion, was carried out with IV bolus cyclophosphamide. Thirty-six patients were treated on study and received a total of 114 cycles of CEVAD: median 2 cycles (range 1–8). No patient achieved a CR. The overall rate of PR was 15/36 (42%). Patients achieved maximal response after a median of 4 (range 3–6) courses. PR rates were 40% (4/10) in patients with primary refractory disease, 48% (11/23) in patients with secondary refractory disease, 31% (6/19) in patients who had failed previous VAD therapy, and 50% (7/14) in patients receiving 2nd or subsequent relapse therapy. Three patients died during their initial cycle of therapy from rapidly progressive disease and sepsis. Overall median survival was 24 weeks with a 1-year survival of 33.3% {95% confidence interval of 20–46%}. Myelosuppression was the most frequent adverse event with NCI grade 2 neutropenia and/or thrombocytopenia in 15% of first cycles, grade 3 in 20%, and grade 4 in 65%. Two-thirds of patients had at least one episode of grade 3 or 4 sepsis. In 15% of septic episodes positive blood cultures were obtained. Overt cardiotoxicity was seen in two patients. CEVAD as used in this study was not more effective than VAD in terms of overall response rate or survival. Am. J. Hematol. 63:125–130, 2000. © 2000 Wiley-Liss, Inc.
Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) Study
Authors: Fabrizio Tomai, Flavio Ribichini, Leonardo De Luca, Alessandro Petrolini, Anna S. Ghini, Luca Weltert, Carmen Spaccarotella, Igino Proietti, Carlo Trani, Francesco Nudi, Michele Pighi, Corrado Vassanelli
Journal: Circulation (2013)

Percutaneous coronary interventions in patients with chronic kidney disease have shown suboptimal results. Drug-eluting stents (DES) might reduce the rate of target vessel revascularization in comparison with bare-metal stents (BMS) in patients with chronic kidney disease. However, given the multiple concomitant individual variables present in such patients, the comparison of neointimal growth after percutaneous coronary intervention is complex and difficult to assess.Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient with Chronic Kidney Disease (RENAL-DES) was a prospective, randomized, multicenter study to directly compare the efficacy in the prevention of clinical restenosis of everolimus-eluting stent (Xience V) and BMS with an identical design (Multi-Link Vision), both implanted in the same patient with multivessel coronary artery disease and chronic kidney disease (estimated glomerular filtration rate <60 mL/min). The primary end point of the study was the ischemia-driven target vessel revascularization as detected with myocardial scintigraphy at 12 months. In 215 patients, 512 coronary vessels were successfully treated with the randomly assigned DES (n=257) or BMS (n=255). At 1 year, the rate of ischemia-driven target vessel revascularization for DES and BMS groups was 2.7% (95% confidence interval, 1.1%-5.6%) and 11.4% (95% confidence interval, 7.8% to 16%), respectively, P<0.001. For the multivariate analysis, independent predictors of the ischemia-driven target vessel revascularization were BMS implantation (odds ratio, 4.95; 95% confidence interval, 2.1-11.6; P<0.001) and vessel size (odds ratio, 0.32; 95% confidence interval, 0.1-0.7; P=0.006).This is the first randomized trial showing a reduction of clinical restenosis with a new-generation DES in comparison with a BMS of equal design, in patients who have chronic kidney disease with multivessel coronary artery disease.http://clinicaltrials.gov. Unique identifier: NCT00818792.
Pressor Effects of Epinephrine, Norepinephrine and Desoxycorticosterone Acetate (DCA) Weakened by Sodium Withdrawal
Authors: W. RAAB, R. J. HUMPHREYS, N. MAKOUS, R. DEGRANDPRÉ, W. GIGEE
Journal: Circulation (1952)

Recent findings suggest an important role of the sodium ion, intracellularly deposited by the adrenal mineralocorticoids, as the physicochemical mediator between the pressor actions of the mineralocorticoids and of the adrenosympathogenic neurohormones. The following observations show that the pressor effectiveness of both the pressor neurohormones and desoxycorticosterone acetate depends on the availability of sodium. This supports the theory that vascular pressor responsiveness and tonus is determined jointly by the sodium-depositing corticoids as sensitizers and the adrenosympathogenic neurohormones as the physiologic stimulators of the vascular contractile elements.
American and International Congresses on Tuberculosis and Tuberculosis Exhibits for the Years 1904 and 1905.
Authors: S. A. Knopf
Journal: JAMA (1903)

New York, Nov. 27, 1903.  To the Editor:  —During the past few months I have received many inquiries concerning the various tuberculosis congresses (American and international) which have been projected for the years 1904-5. The multiplicity of these various congresses and the similarity of their names lead naturally to great confusion.  It is announced that a congress on tuberculosis is to be held in St. Louis in October, 1904, under the name of International Congress on Tuberculosis. On careful inquiry I learned the following facts about this congress: Mr. Francis, the president of the St. Louis Exhibition, has been approached by the officers of the American Congress on Tuberculosis, which was founded some years ago by Clark Bell, a lawyer of the city of New York, to sanction the holding of an international congress on tuberculosis in connection with the Louisiana Purchase Exposition. From a letter received from Dr. E.
Trial of a Supplemental Dose of Four Poliovirus Vaccines
Authors: Roland W. Sutter, Ali Jaffer M. Suleiman, Pradeep Malankar, Saleh Al-Khusaiby, Firdosi Mehta, Geoff B. Clements, Mark A. Pallansch, Susan E. Robertson
Journal: New England Journal of Medicine (2000)

The immunogenicity of oral poliovirus vaccine (OPV), particularly the type 3 component, is lower in infants in most developing countries than in infants in industrialized countries. We conducted a multicenter trial in Oman to evaluate the response to a supplemental dose of four poliovirus vaccine formulations.
Prevention of Antibiotic Resistance in Hospitals
Authors: Nina Singh, Victor L. Yu
Journal: Annals of Internal Medicine (2002)

Letters15 January 2002Prevention of Antibiotic Resistance in HospitalsNina Singh, MD and Victor L. Yu, MDNina Singh, MDVeterans Affairs Medical Center; Pittsburgh, PA 15240Search for more papers by this author and Victor L. Yu, MDVeterans Affairs Medical Center; Pittsburgh, PA 15240Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-2-200201150-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their superb review on antibiotic resistance in the intensive care unit (1), Drs. Kollef and Fraser incorrectly defined our approach to nosocomial pulmonary infiltrates. We did not quantitate the risk for nosocomial pneumonia but used a scoring system merely as an operational criterion for decision making about antibiotic therapy, regardless of whether patients had nosocomial pneumonia (2). Patients who had low clinical pulmonary infection scores (and were unlikely to have bacterial pneumonia) were randomly assigned to standard therapy, usually defined as multiple antibiotics for 10 or more days, or monotherapy for 3 days. Our approach, regardless ...References1. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134:298-314. [PMID: 11182841] LinkGoogle Scholar2. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162 2 Pt 1 505-11. [PMID: 10934078] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Veterans Affairs Medical Center; Pittsburgh, PA 15240 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAntibiotic Resistance in the Intensive Care Unit Marin H. Kollef and Victoria J. Fraser Prevention of Antibiotic Resistance in Hospitals Marin Kollef Prevention of Antibiotic Resistance in Hospitals James R. Johnson Metrics 15 January 2002Volume 136, Issue 2Page: 173KeywordsAntibiotic resistanceAntibioticsDecision makingHabitsIntensive care unitsLength of stayMortalityPneumoniaPulmonary diseasesSuperinfections ePublished: 15 January 2002 Issue Published: 15 January 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...